Effect of Hepatic Preconditioning with the Use of Methylene Blue on the Liver of Wistar Rats Submitted to Ischemia and Reperfusion

Almeida, Tcs; Victorino, João Paulo; Liu, J. Bistafa; Campos, Daniel Tófoli Queiroz; Graf, Catarina Piolla; Jordani, Maria Cecília; D’Albuquerque, Luiz Augusto Carneiro; Mendes, Karina Dal Sasso; Castro‐e‐Silva, Orlando

doi:10.1016/j.transproceed.2018.02.002

Cited by 6 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we used the determination of MDA in order to evaluate oxidative stress and MB was able to prevent the production of reactive oxygen species, but without preventing changes in membrane permeability mitochondrial, showing the involvement of other factors in the process. In agreement with these results, other laboratory studies with MB at the same dose (15mg/kg) given 15 minutes before ischemia were also able to reduce lipid peroxidation, showing that this protective effect occurs both before ischemia and reperfusion 14 . Some studies show that MB prevents the production of reactive oxygen species by acting as an alternative receptor for xanthine oxidase electrons, competing with molecular oxygen for the transfer of electrons and preventing the formation of superoxide.…”

Section: ■ Discussionsupporting

confidence: 85%

Evaluation of the therapeutic effect of methylene blue on the liver of rats submitted to ischemia and reperfusion

Castro‐e‐Silva

D’Albuquerque²,

Silveira

et al. 2018

Acta Cir. Bras.

View full text Add to dashboard Cite

Purpose: To analyze the effect of methylene blue (MB) therapy during the liver ischemiareperfusion injury (I/R) process. Methods: Thirty-five male Wistar rats were used, (70%) submitted to partial ischemia (IR) or not (NIR) (30%) were obtained from the same animal. These animals were divided into six groups: 1) Sham (SH), 2) Sham with MB (SH-MB); 3) I/R, submitted to 60 minutes of partial ischemia and 15 minutes of reperfusion; 4

show abstract

Section: ■ Discussionsupporting

confidence: 85%

Evaluation of the therapeutic effect of methylene blue on the liver of rats submitted to ischemia and reperfusion

Castro‐e‐Silva

D’Albuquerque²,

Silveira

et al. 2018

Acta Cir. Bras.

View full text Add to dashboard Cite

show abstract

“…This condition leads to failure of the Na + /K + pump, membrane depolarization, and intracellular Ca 2+ accumulation: a typical scenario that links the mitochondrial respiratory activity and the mechanism of IRI. Our group recently demonstrated significant inhibition of electron transport through the respiratory chain in the rat liver caused by a single cycle of I/R [18].…”

Section: Pathophysiology Of Irimentioning

confidence: 99%

“…The transition of mitochondrial membrane permeability is a process mediated by the opening of a nonspecific channel called the permeability transition pore (mPTP). This process is characterized by mitochondrial swelling and is induced by a threshold of [Ca 2+ ], which is significantly reduced by ROS build-up [18]. These phenomena have been consistently associated with cell death resulting from a variety of pathological conditions, including IRI [20,21].…”

Section: Pathophysiology Of Irimentioning

confidence: 99%

“…Several protective drugs modulate other independent routes that may alternatively be activated during reperfusion and that are not assigned to the RISK, SAFE or the cGMP/PKC pathways. They can have different types of effects such as such as inhibition of ROS-producing complexes [18,67,134,135,136,137,138,139,140,141,142,143], or may act as anti-apoptotic [144], anti-inflammatory [24,53,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164] and antioxidants agents [165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194], as glucose metabolism enhancers [99,…”

Section: Therapeutics: the Pharmacological Approachmentioning

confidence: 99%

See 1 more Smart Citation

Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies

Soares

Losada

Jordani

et al. 2019

IJMS

209

145

View full text Add to dashboard Cite

Ischemia/reperfusion injury (IRI) permeates a variety of diseases and is a ubiquitous concern in every transplantation proceeding, from whole organs to modest grafts. Given its significance, efforts to evade the damaging effects of both ischemia and reperfusion are abundant in the literature and they consist of several strategies, such as applying pre-ischemic conditioning protocols, improving protection from preservation solutions, thus providing extended cold ischemia time and so on. In this review, we describe many of the latest pharmacological approaches that have been proven effective against IRI, while also revisiting well-established concepts and presenting recent pathophysiological findings in this ever-expanding field. A plethora of promising protocols has emerged in the last few years. They have been showing exciting results regarding protection against IRI by employing drugs that engage several strategies, such as modulating cell-surviving pathways, evading oxidative damage, physically protecting cell membrane integrity, and enhancing cell energetics.

show abstract

“…During the period of the perfusion, a short-term ischemic preconditioning, to make the organism adaptive to the subsequent long ischemia, is an effective endogenous protective phenomenon, but the mechanism is poorly understood [ 14 ]. De Almeida et al illuminated that hepatic preconditioning ameliorated liver IRI by reducing lipid peroxidation [ 15 ]. In addition, hypothermic preconditioning, remote ischemic preconditioning (RIPC), and pharmacological pretreatment with statins are a benefit to IRI [ 16 , 17 , 18 ].…”

Section: Current Strategies For Ameliorating Liver Ischemia-reperfmentioning

confidence: 99%

Novel Targets for Treating Ischemia-Reperfusion Injury in the Liver

Yang

Chen

Meng

et al. 2018

IJMS

View full text Add to dashboard Cite

Liver ischemia-reperfusion injury (IRI) is a major complication of hemorrhagic shock, liver transplantation, and other liver surgeries. It is one of the leading causes for post-surgery hepatic dysfunction, always leading to morbidity and mortality. Several strategies, such as low-temperature reperfusion and ischemic preconditioning, are useful for ameliorating liver IRI in animal models. However, these methods are difficult to perform in clinical surgeries. It has been reported that the activation of peroxisome proliferator activated receptor gamma (PPARγ) protects the liver against IRI, but with unidentified direct target gene(s) and unclear mechanism(s). Recently, FAM3A, a direct target gene of PPARγ, had been shown to mediate PPARγ’s protective effects in liver IRI. Moreover, noncoding RNAs, including LncRNAs and miRNAs, had also been reported to play important roles in the process of hepatic IRI. This review briefly discussed the roles and mechanisms of several classes of important molecules, including PPARγ, FAM3A, miRNAs, and LncRNAs, in liver IRI. In particular, oral administration of PPARγ agonists before liver surgery or liver transplantation to activate hepatic FAM3A pathways holds great promise for attenuating human liver IRI.

show abstract

Effect of Hepatic Preconditioning with the Use of Methylene Blue on the Liver of Wistar Rats Submitted to Ischemia and Reperfusion

Cited by 6 publications

References 19 publications

Evaluation of the therapeutic effect of methylene blue on the liver of rats submitted to ischemia and reperfusion

Evaluation of the therapeutic effect of methylene blue on the liver of rats submitted to ischemia and reperfusion

Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies

Novel Targets for Treating Ischemia-Reperfusion Injury in the Liver

Contact Info

Product

Resources

About